Bank of America Corp DE decreased its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 2.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 144,774 shares of the health services provider’s stock after selling 4,069 shares during the period. Bank of America Corp DE owned approximately 0.45% of Amedisys worth $12,372,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Algert Global LLC bought a new stake in Amedisys during the second quarter valued at $1,208,000. Piedmont Investment Advisors LLC boosted its stake in Amedisys by 9.3% during the second quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock valued at $570,000 after buying an additional 567 shares during the period. Rhumbline Advisers boosted its stake in Amedisys by 3.1% during the second quarter. Rhumbline Advisers now owns 68,707 shares of the health services provider’s stock valued at $5,872,000 after buying an additional 2,077 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in Amedisys by 9.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 202,546 shares of the health services provider’s stock valued at $17,310,000 after buying an additional 16,677 shares during the period. Finally, Segall Bryant & Hamill LLC bought a new stake in Amedisys during the second quarter valued at $1,942,000. 93.31% of the stock is owned by institutional investors.
Several research firms recently issued reports on AMED. Cantor Fitzgerald began coverage on Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 price objective for the company. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Royal Bank of Canada lifted their price objective on Amedisys to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 3rd. Bank of America raised Amedisys from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $88.00 to $97.00 in a research note on Tuesday, July 3rd. Finally, ValuEngine upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 30th. Five research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $95.38.
NASDAQ AMED opened at $109.28 on Friday. Amedisys Inc has a twelve month low of $45.60 and a twelve month high of $127.38. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.30. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 51.86, a PEG ratio of 1.89 and a beta of 1.00.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, July 31st. The health services provider reported $1.00 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.22. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. The business had revenue of $411.60 million for the quarter, compared to the consensus estimate of $403.62 million. During the same quarter last year, the business posted $0.62 earnings per share. On average, analysts predict that Amedisys Inc will post 3.41 EPS for the current fiscal year.
In other Amedisys news, insider David B. Pearce sold 398 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total transaction of $48,440.58. Following the sale, the insider now owns 11,818 shares in the company, valued at $1,438,368.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.60% of the company’s stock.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Featured Article: Asset Allocation Models, Which is Right For You?
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.